As of November 6, 2026, Purple Biotech Ltd. is a publicly traded company (Nasdaq: PPBT); its largest reported holder is Mitchell P. Kopin, with 9.99% on Schedule 13G/A of May 13, 2026, then Orca Capital AG (9.9%). The largest insider holding is Gil Efron, the chief executive, with 15,750,000 shares (0.85% of shares outstanding), per Form 3 of March 31, 2026 (Schedule 13G/A, May 13, 2026).
Is this your company?
About to sign with, pay or invest in Purple Biotech Ltd.? See the free Snapshot first.
Free to see. No signup.
Is Purple Biotech Ltd. a real, registered company?
- Purple Biotech Ltd. files with the SEC under CIK 1614744 (its SEC filings).
- Its shares are listed under the ticker PPBT on Nasdaq (SEC company record).
- Incorporated in L3; business address in Rehovot, L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PURPLE BIOTECH LTD. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Mitchell P. Kopin (filed 2026-05-13).
Who are Purple Biotech Ltd.'s owners and officers?
Purple Biotech Ltd.: business address in Rehovot, L3; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer (Form D, 2024-07-15)
- : Executive Officer (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Director (Form D, 2024-07-15)
- : Executive Officer (Form D, 2024-07-15)
- : Executive Officer (Form D, 2024-07-15)
- : Executive Officer (Form D, 2024-07-15)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | G1 Execution Services, LLC | 1.4% |
| Schedule 13G/A, 2026-05-13 | Mitchell P. Kopin | 9.99% |
| Schedule 13G, 2026-02-13 | Susquehanna Securities, LLC | 5.2% |
| Schedule 13G/A, 2025-11-07 | Mitchell P. Kopin | 9.99% |
| Schedule 13G, 2025-09-10 | Mitchell P. Kopin | 9.99% |
| Schedule 13G, 2025-09-09 | Orca Capital Ag | 9.9% |
| Schedule 13G, 2025-09-09 | Lincoln Alternative Strategies LLC | 9.9% |
| Schedule 13G/A, 2025-09-09 | Orca Capital Ag | 4.9% |
Questions about who owns Purple Biotech Ltd.
Who owns Purple Biotech Ltd.?
On this page, 4 holders' latest ownership filings report 5% or more of Purple Biotech Ltd.: Mitchell P. Kopin (9.99%, Schedule 13G/A, filed 2026-05-13), Orca Capital Ag (9.9%, Schedule 13G, filed 2025-09-09), Lincoln Alternative Strategies LLC (9.9%, Schedule 13G, filed 2025-09-09) and Susquehanna Securities, LLC (5.2%, Schedule 13G, filed 2026-02-13).
Who are the largest shareholders of Purple Biotech Ltd.?
By the share each holder's latest filing reports, the largest holders of Purple Biotech Ltd. on this page are Mitchell P. Kopin (9.99%), Orca Capital Ag (9.9%) and Lincoln Alternative Strategies LLC (9.9%).
When did Mitchell P. Kopin buy into Purple Biotech Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Mitchell P. Kopin on this page is the Schedule 13G, filed 2025-09-10, reporting 9.99%; its latest, Schedule 13G/A filed 2026-05-13, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Purple Biotech Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Purple Biotech Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Purple Biotech Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Purple Biotech Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive: 15,750,000 shares (0.85% of shares outstanding) (Form 3, 2026-03-31).
- , the head of clinical and reg affairs: 9,254,472 shares (0.50% of shares outstanding) (Form 3, 2026-03-30).
- , the chief financial officer: 3,550,000 shares (0.19% of shares outstanding) (Form 3/A, 2026-03-30).
- , a director: 3,207,690 shares (0.17% of shares outstanding) (Form 3, 2026-04-17).
- , a director: 3,093,860 shares (0.17% of shares outstanding) (Form 3, 2026-04-06).
Shares outstanding: 1,858,911,801 as of 2025-12-31, from the company's latest SEC cover page.
How much has Purple Biotech Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-07-15 | $4.51M | $4.51M |
| Form D, 2023-10-31 | $5.43M | $5.43M |
Latest IPO step: Purple Biotech Ltd. filed its final IPO prospectus, ticker PPBT (424B4, 2025-09-05).
IPO filings: 424B4, 2025-09-05, F-1, 2025-08-29, F-1, 2024-07-22; ticker PPBT on Nasdaq.
Keep reading
More on Purple Biotech Ltd. and the records around it.
Purple Biotech Ltd. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- G1 Execution Services, LLC also filed stake reports on 45 other companies: AmpliTech Group, Inc. (Aug 2026), Bitdeer Technologies Group (Aug 2026), Compass Diversified Holdings (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/purple-biotech